TY - JOUR
T1 - How I manage anemia related to myelofibrosis and its treatment regimens
AU - Verstovsek, Srdan
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/4
Y1 - 2023/4
N2 - Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by mutations (most frequently in JAK2, CALR, or MPL), burdensome symptoms, splenomegaly, cytopenia, and shortened life expectancy. In addition to other clinical manifestations, patients with MF often develop anemia, which can either be directly related to MF pathogenesis or a result of MF treatment with Janus kinase (JAK) inhibitors, such as ruxolitinib and fedratinib. Although symptoms and clinical manifestations can be similar between the 2 anemia types, only MF-related anemia is prognostic of reduced survival. In this review, I detail treatment and patient management approaches for both types of anemia presentations and provide recommendations for the treatment of MF in the presence of anemia.
AB - Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by mutations (most frequently in JAK2, CALR, or MPL), burdensome symptoms, splenomegaly, cytopenia, and shortened life expectancy. In addition to other clinical manifestations, patients with MF often develop anemia, which can either be directly related to MF pathogenesis or a result of MF treatment with Janus kinase (JAK) inhibitors, such as ruxolitinib and fedratinib. Although symptoms and clinical manifestations can be similar between the 2 anemia types, only MF-related anemia is prognostic of reduced survival. In this review, I detail treatment and patient management approaches for both types of anemia presentations and provide recommendations for the treatment of MF in the presence of anemia.
KW - Anemia
KW - Janus kinase
KW - Myelofibrosis
KW - Myeloproliferative neoplasm
KW - Ruxolitinib
UR - http://www.scopus.com/inward/record.url?scp=85147991891&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85147991891&partnerID=8YFLogxK
U2 - 10.1007/s00277-023-05126-4
DO - 10.1007/s00277-023-05126-4
M3 - Review article
C2 - 36786879
AN - SCOPUS:85147991891
SN - 0939-5555
VL - 102
SP - 689
EP - 698
JO - Annals of Hematology
JF - Annals of Hematology
IS - 4
ER -